Total Portfolio: 2.471 Million €
Net profit: 26 Million € (30/09/2020)
Invested in 2020: 272 Million €
Companies > 1 Million €: >175 Million € (31/12/2020)
Life Sciences in Wallonia

The pharmaceutical sector is the main industrial activity in Wallonia in terms of added value

27% of total Walloon exports

1,2 B € of private investment into biopharma R&I in 2018

2,2 B € cumulated private capital raised by SMEs (2005-2019)

50,000+ employees in the life-science sector (16,424 Direct Jobs)

“Belgium: the number one biotech country in Europe!”
September 30, 2020 | BioVox
Key Missions

- Long Term Investments
- Walloon Region of Belgium
- Value Creation for S.R.I.W. and Invested Companies
- Support to Local Activity, Jobs and Ecosystem
Key Investment Guidelines

- Equity and/or Debt based on company maturity
- Minority investments beside private (VC) lead investors
- Minimum 1 Million €
- Maximum & % depending on company activity & maturity
Key Investment Criteria

Management

IP

Local Activity & Jobs

Market/Competition

Unmet Needs
Main Investment Focus

Therapeutic areas:
- Immunology
- Oncology
- Neurosciences

Type of products:
- Innovative Biologicals
- Smart Medtech & Diagnostics

Platforms:
- Contract Service Organisations
- Personalised Medicine
- e-Health
SRIW LIFE SCIENCES

- Million € Portfolio Fair Value: 239
- Companies in Portfolio: 59
- Network (experts, consultants, managers,...): > 1.500
- Million € Cummulated Return on Investments: + 174
Our Strengths

- Exit flexibility thanks to evergreen structure
- Large investment capacities
- Faithful & Trustworthy
- Stable investment strategy
Our Track Record

**M&A**

- **Ogeda**
  - Sold to **Astellas** for 800 M € in 2017
  - *Multiple 18.2 x (up to 24.3 x)*

- **Uteron Pharma**
  - Sold to **Watson Pharma (now AbbVie)** for 305 M $ in 2013
  - Rights sold to **Mithra Pharma** in 2015
  - *Multiple 4.0 x*

**IPOs**

- **Euronext in 2013 & Nasdaq in 2015**
  - **115 M €** raised at IPOs

- **Euronext in 2015**
  - **79 M €** raised at IPO

- **Nasdaq in 2020**
  - **201 M $** raised at IPO

- **Euronext in 2020**
  - **85 M €** raised at IPO
**Our News Flow**

**Q4 2020**

- **iSTAR Medical** has been awarded the 2020 Venture Company of the Year at the Belgian Venture Capital & Private Equity Association virtual ceremony (October 29th)

- European Investment Bank provides **Minoryx Therapeutics** with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases (October 30th)

- **Iteos Therapeutics** has been recognised as this year’s European Mediscience Awards Emerging Star. Previous winners of this accolade include BioNTech SE and CMR Surgical (November)

- **Nyroah** announces First Patient Implanted in the DREAM US Pivotal IDE Study, with the Genio® System for the Treatment of Obstructive Sleep Apnea (November 17th)

- **Mithra Pharmaceuticals** raises EUR 125 million convertible bonds due 2025 (December 10th)

- **Univercells Holding** raises €70 million in Series C Financing (December 17th)

- **Kitozyme** wins the Awex Export Grand Prix on the year of its 20th Birthday (December 17th)

- **Bone Therapeutics** completes recruitment and patient treatment in JTA-004 pivotal Phase III knee osteoarthritis study (December 22nd)
Our Team

Board member

Other companies in portfolio

Contact

Philippe Degive, MBA
SRIW since 7/08
pdegive@sriw.be
+32 499 965465
Our Team

Board member

Other companies in portfolio

Contact

Gery Lefebvre, MBA
SRIW since 4/14
glefebvre@sriw.be
+32 496 211340
Our Team

Board member

Other companies in portfolio

Contact

Christina Franssen, PhD
SRIW since 1/19
cfranssen@sriw.be
+32 474 397399
Univercells Technologies

**Corporate**
Nivelles, Belgium
Fund raised: 50 M €
Hugues Bultot, José Castillo, Mathias Garny

**Technology**
- Biomanufacturing technologies for viral products: gene therapies, vaccines, oncolytic viruses & exosomes.
- scale-X™ bioreactor portfolio
- NevoLine™ Upstream platform (launched end 2020)

**Business**
- Gene therapy & vaccine markets
- In-house developers and contract manufacturers

**Milestones**
Innovate and deliver best-in-class technologies for viral manufacturing

customer@univercellstech.com
www.univercellstech.com
Syndesi Therapeutics

Corporate
Founded Jan 2018 with IP licensed from UCB
~€20 M raised from investor syndicate and Walloon Region
Management team with extensive pharma/biotech experience in drug discovery and development

Technology
Novel small molecule modulators of SV2A, a synaptic protein that regulates communication between nerve cells
Mechanistic hypothesis is improvement of impaired synaptic transmission to restore cognitive function
Phase I with lead molecule initiated in May 2019

Business
Lead molecule SDI-118 – oral administration
Phase I in progress
Aiming to mitigate symptoms of cognitive impairment to improve patient’s day-to-day function
Potential indications include Alzheimer’s Disease, cognitive impairment in schizophrenia, cognitive deficit in depression and other conditions with cognitive dysfunction

Milestones
Data from full Phase I program, including multiple dose and pharmacodynamic read outs (1H 2020)
Initiation of Phase IIa studies investigating effect on cognitive performance (2H 2020)

Contact: Person: Jonathan Savidge, CEO
Visit our Website: www.syndesitherapeutics.com
Synergia Medical

Corporate
Founded in 2014
Managed by its two co-founders Mr. Borbath (CEO) and Dr. Doguet (CTO/COO).
2018: Series A of EUR 8.1 M (with SRIW as one of the main actors).
2019: phase 1 funding from the European Commission.

Technology
Use of **optoelectronics** in the field of **neural stimulation**.
Disruptive technology based on optic fibers, photovoltaic cells and non-metal casings. It will enable practitioners to receive feedback on the direct effect and efficacy of the stimulation, in order to deliver personalized therapy to the patients. Currently being tested on sheep.

Business
**First market target:** drug-resistant epilepsy patients.
Many other applications can benefit from the technology (depression, obesity, sleep apnea, heart failure, etc.).
**Strong research project** financed by Walloon Region which aims at improving the therapy.
**Regulatory and market access:** Europe and the USA

Milestones
**Q2 2022:** first in human & beginning of a 12-month pilot clinical study in EU
**Q1 2024:** beginning of a 12-month pivotal study in EU and USA
**2021:** Series B of financing
**2025:** CE marking and FDA approval

Contact: Attila Borbath (CEO) - attila.borbath@synergiam.com
Visit our Website http://www.synergia-medical.com/

In Our Portfolio
In Our Portfolio

Quality Assistance

Corporate
Founded in 1982
CRO (Contract Research Organisation)
Private, independent limited company
CEO Philippe Draux
COO Nathalie Draux
Revenues 2018: 22 m EUR
EBITDA/CA 2018: 27%
Headcount 2018: 159 FTE

Technology
Mass Spectrometry
Bioassays
Protein Characterisation
Molecular Biology
Chromatography
Bioanalysis (PK/TK/Immuno)
Immunoassays
Microbiology

Business
All the analytical services required by EMA and FDA regulations for the development and marketing of innovative human medicinal products
- New Chemical Entities
  - Peptides
  - Oligonucleotides
- Biologics
  - Antibody-Drug Conjugates
  - Monoclonal antibodies
  - Proteins
- Nanomedicine Products
- Vaccines
- Cell and Gene Therapies

Milestones
3 facility expansion phases, reaching 5700 sqm.
2020: Start new expansion
GMP certified since 1984
GLP certified since 2004
Speed up people's access to 500 innovative drugs (Challenge 2015-2020)

Visit www.quality-assistance.com to learn more
**Promethera® Biosciences SA**

**Corporate**
- Founded in 2009 by Prof. Etienne Sokal, Promethera is a Spin-off of the UCLouvain
- TOTAL Fundraising since inception: €153 M including €26 M in convertible bonds & €30 M in non-dilutive funding
- Executive Committee comprising 3 Board Directors: Etienne Sokal (Promethera), Alain Parthoens (AQ Invest) & Zimeng Dong (Co-High)

**Technology**
- Promethera® is a leading biotechnology company based in Belgium, developing cell & antibody therapies to treat severe, end-stage liver diseases with large unmet needs.
- **HepaStem™**: Lead cell therapy product with potential applications in fibro-inflammatory liver diseases such as ACLF & NASH
- **Atrosimab**: Antibody therapy with potential anti-inflammatory activity

**Milestones reached:**
- Completion of Phase 2a & Start of Phase 2b – pivotal – with HepaStem™ in ACLF (initiated in Q1 2020) in Europe + Completion Phase 2a with HepaStem™ in NASH in Europe

**Business**
- Targeting advanced-stage liver diseases with large unmet needs and commercial opportunities including ACLF (Acute-on-Chronic Liver Failure), AAH (Acute Alcoholic Hepatitis), NASH (Non-Alcoholic SteatoHepatitis) and other fibro-inflammatory liver diseases.

**Milestones**
- **DHELIVER**: Ongoing phase 2b (EU), possibly pivotal, in ACLF: focus on path to market
- **PANASH**: Clinical study report for phase 2a (EU) in NASH in 2020
- US study in ACLF: IND under preparation
- Japan development in ACLF under preparation
- Atrosimab: tox study and manufacturing performed in 2020 – Phase 1 in Q1 2021
- Seeking collaborations with (bio)pharma companies

Prof. Etienne Sokal, MD, PhD – Founder of Promethera®
info@promethera.com
Visit our Website: promethera.com
In Our Portfolio

PDC*line Pharma

Corporate
- Founded in 2014
- Spin-off from EFS (France)
- Fund raising since inception: 32M€
- Last round has been led by the Asian leading VC Korean Investment Partners (KIP)
- A team of 24 people
- CEO: Eric Halioua

Technology
- **Platform**
  - New class of potent and off-the-shelf therapeutic cancer vaccines based on a proprietary cell line of Plasmacytoid Dendritic Cells (PDC*line)
- **Milestones reached**
  - A robust preclinical package and a first-in-human phase I in 9 melanoma patients
  - Phase I/II trial ongoing in lung cancer (PDC*lung) in France and Belgium on 62 patients
  - Preclinical program with neoantigens based vaccines (PDC*Neo)

Business
- **Deals**
  - Licensing deal signed with LG-Chem, for the development and commercialization of PDC*lung for lung cancer in Asia. Total deal value is 123M$ plus significant tiered royalties on net sales.
- **Markets**
  - PDC*line platform can be used for the treatment of virtually all cancer patients expressing HLA-A2 – with extension possibilities to other HLAs.
  - Revenues potential in the range of € 3 BN to € 4.5 BN in the US and EU

Milestones
- Clinical study report for phase I/II clinical trial with PDC*lung by 2022
- US and Asia lung cancer study initiation in 2023/2024
- Initiation of trial for a new indication in 2023
- Complete new round of financing in 2022
- Seeking collaborations with biopharma companies

Contact Person: Eric Halioua, CEO
contact@pdc-line-pharma.com
Visit our Website www.pdc-line-pharma.com
In Our Portfolio

Osimis

Corporate
- Founded in 2015
- Fund raising in March 2019
- Turnover 2018: 480 k€
- Actual team: 15 people

Technology
- Medical imaging
- Making image management and sharing in healthcare and other sectors simple, powerful and cost efficient through the use of open source software

Business
- Several ongoing R&D programs
- Current market targets: Belgium/Europe/US

Milestones
- Significant growth of the turnover every year
- Extend presence abroad
- Team up to 20 people by end of 2020

Contact Person: Frederic Lambrechts
fla@osimis.io
Visit our Website www.osimis.io
Nyxoah

Corporate
Founded in 2009
Global company with headquarters in Belgium and subsidiaries in Israel, Australia and USA
Currently 80 employees, continuous expansion
Olivier Taelman, CEO
Fabian Suarez, CFO

Technology
Health technology focusing on Obstructive Sleep Apnea (OSA) therapy – the most common sleep disordered breathing condition
First and only leadless, battery-free neurostimulator – Minimally invasive and user-centered

Business
1 Billion OSA sufferers worldwide
Target population: patients with moderate to severe OSA who have failed PAP therapy
500K new eligible patients in the USA every year – 600K in Europe/ANZ
€20 Billions annual total addressable market

Milestones
CE Mark in 2019
Germany funding and first revenue generated in 2020
Completion of ANZ study enrolments in Nov. 2020 for therapeutic indications extension
US IDE study approval by FDA and first US and International patients enrolled in 2020
€85M IPO ($100M) on Euronext Brussels in Sept. 2020 (EBR: NYXH)

Contact Persons: Olivier Taelman (CEO), Fabian Suarez (CFO) – info@nyxoah.com
Visit our Website: www.nyxoah.com
Novadip Biosciences

In Our Portfolio

Corporative
- Origin: 2013 UCL & St Luc Hospital Spin-off
- Fund raising since inception: 28 M€ Series A (co-led by NSV/Fund+) + 11,6M€ grant/loan
- Management team: 44 employees
  - Denis Dufrane (CEO, Scientific Founder)

Technology
- Platform: Unique tissue regeneration technology platform
- Description: Scaffold-free, Disruptive 3M³ Delivery Platform at clinical stage delivering 3 product classes
- Product Strategy:
  - Autologous: for critical size defects in orphan indications with more than 40 patients treated
  - Off-the-Shelf: for complex defects in large indications
  - Cell-Free for surgically unattainable tissue in solid tumor indications

Business
- Autologous (autologous therapy for large bone reconstruction): rare pediatric disease trial planned; phase 1/2 trial in adults with bone non-union ongoing
- Off-The-Shelf: allogeneic products for hard tissue regeneration with biological properties to position as a key competitor in the Graft Bone Substitute market
- Cell-Free Exosome Based: For surgically unattainable tissue: 30-150nm to reduce solid tumor size and repair tissue

Milestones
- Significant Market:
  - Autologous: Phase 1/2 trial start in rare pediatric disease
  - Bone non-union trial 12m data
- Off-the-shelf: In vivo proof of concept efficacy studies in target indication (e.g., maxillofacial reconstructive surgery, spine fusion)
- Cell-Free Exosome Based: In vivo POC

Contact: denis.dufrane@novadip.com
Visit our Website https://www.novadip.com
In Our Portfolio

Ncardia

Corporate

- **Corporate**
  - Founded in 2014
  - Raised €22.5M
  - CEO: Stefan Braam
  - CFO: Martijn Meijer
  - Chief Services Officer: Johan te Koppele
  - Headcount 2019: 40 FTE

Technology

- **Area of interest**: applications of stem cell derived cells in drug discovery and cell therapy
- **Products description**: human induced pluripotent stem cell derived cardiomyocytes and neurons
- **Services description**: Drug discovery services using Ncardia healthy and diseased cellular models
  - iPSC manufacturing services

Business

- **Current R&D programs**:
  - iPSC process development including differentiation and upscaling
  - Novel assay development using Ncardia cell models
- **Current market targets**:
  - CRO/CDMO services using iPSC technology to biotech and large pharma
  - **iPSC cell products** for safety testing of novel drug candidates

Milestones

- >50% growth of services revenues every year
- Extend presence in the target markers
- Positive EBITDA in 2020

Contact: Stefan Braam (CEO) – Stefan.braam@ncardia.com
Visit our Website: [http://www.ncardia.com/](http://www.ncardia.com/)
In Our Portfolio

Mithra

Corporate
Founded in 1999 by François Fornieri and Professor Dr. Jean-Michel Foidart
Spin-off of ULiège
IPO Euronext 2015
250+ employees
€248,0m raised to date (IPO included)
François Fornieri, CEO
Christophe Maréchal, CFO

Technology
Estetrol (E4), Mithra’s unique native estrogen platform with a superior benefit/risk profile.
Expertise in developing complex and innovative polymer products.
Mithra CDMO, industry partner with specialist research, development and manufacturing capabilities.

Business
Mithra is dedicated to transforming Women’s Health by offering new choices through innovation, with a particular focus on contraception and menopause.
Its three lead development candidates – a fifth generation oral contraceptive Estelle®, the first complete oral treatment for perimenopause PeriNesta® and next-generation hormone therapy Donesta® - are built on Mithra’s unique native estrogen platform, Estetrol (E4).

Milestones
Estelle®: Market authorization (MA) 2021
PeriNesta®: start of trial by end-2020 (pending approval of authorities)
Donesta®: Ph3 results 2022
Myring™: MA US 2020

Corporate strategy: (1) to leverage the full potential of the E4 platform, and (2) to develop partnering for our technology platform (development and manufacturing).

Contact Person: InvestorRelations@mithra.com
Visit our Website: www.mithra.com
In Our Portfolio

Miracor Medical

Corporate
Origin: Austria
Fund raising since inception: €65m equity
Management team: Olivier Delporte (CEO), Bertrand Grimmonpré (CFO)

Technology
Area of interest: Medical Device
Company focused on Heart Failure prevention
Products description: PiCSO® Impulse System (Proprietary Console and catheter)
Milestones/POC reached:
Safety and efficacy demonstrated in +200 clinical studies. EU Randomized study underway.

Business
Current R&D programs:
RCT ongoing in #144 patients / #7 sites + development of console and catheter scalability.
- EU: CE Mark: Obtained in June 2020
Current market targets:
Heart attacks, specifically anterior STEMI (Available Market: >$8b)

Contact Person details: Olivier Delporte, CEO: odelporte@miracormedical.com
Visit our Website: www.miracormedical.com

Milestones
Next R&D/commercial steps to reach:
- US: IDE study approval by FDA
- Product ready for large production
Corporate objectives:
- Ensure company long-term financing
- Make PiCSO leading therapy for infarct size reduction for heart attacks patients
Minoryx Therapeutics

In Our Portfolio

Corporate
- Founded in 2011
- Raised €50M
- 25 FTEs with operations in Belgium (Brussels South Biopark) and Spain (Barcelona)
- Marc Martinell (CEO), Didier le Normand (CFO & GM Belgium), Uwe Meya (CMO), Sonia Poli (CSO), María Pascual (CRO)

Technology
- Lead candidate: leriglitazone (PPAR gamma agonist)
- In Phase 2/3 for X-ALD (adult form) and Phase 2 for Friedreich’s Ataxia (FRDA)
- Orphan Drug Designation granted for X-ALD (EU & US)

Business
- First to market opportunity in X-ALD – most advanced drug candidate worldwide
- Indication expansion to Friedreich’s Ataxia and other CNS diseases

Milestones
- Top line data phase 2/3 X-ALD – by the end of 2020
- Aiming to become a leader in X-ALD, FRDA and other orphan CNS diseases

Marc Martinell (CEO); +34 93 544 14 66
Didier le Normand (CFO & GM Belgium); +32 787 00 162
Visit our Website www.minoryx.com
In Our Portfolio

KitoZyme

**Corporate**
- Founded in 2000
- Spin Off ULiège
- 35 mio EUR = Funds raised since incorporation

**Technology**
- BioTech - Bio-polymers:
  - Chitosan
  - Chitin-glucan
- World leader fungal chitosan
- Patents & Innovation

**Business**
1. Health Care
   - Digestive Health
   - Weight Management
   - Cardiovascular
2. Agriculture
   - Wine
   - Plant

**Milestones**
- 2000-2012: R&D
- 2014: Spin-out of KiOmed Pharma – Biomedical applications
- 2015: Financial Break-even
- 2016: Net profit
- 2011-2019: Sales growth of + 34% per annum

**Contact Person**: BLONDEL François – CEO (info@kitozyme.com)
**Visit our Website**: www.kitozyme.com
KiOmed Pharma

Corporate
- Origin: Spin-out from KitoZyme SA.
- Funds invested in innovation and development: 21.2 Mio€
- Management team:
  - François BLONDEL, Founder & Executive Chairman.
  - Houtai CHOUMANE, CEO & Managing Director.

Technology
- Unique position in ultrapure animal-free chitosan polymer the KiOmedine®.
- Area of interest: Regenerative medicine (osteoarthritis, dermatology and ophthalmology).
- Products description: Class III injectable implants
- Milestones/POC reached:
  - CE mark expected by End of 2019.

Business
- Current market targets:
  - Global market: Hyaluronic acid injections: 11 Bio$ by 2020

Milestones
- Next R&D program: Development of innovative product for dry eye care.
- Commercial steps:
  - CE mark by End of 2019
  - Product launch Q1-2020

Contact Person details: Houtai CHOUMANE, CEO - Tel +32(0)4 228 80 40.
Email contact@kiomedpharma.com, www.kiomedpharma.com
iTeos Therapeutics

**In Our Portfolio**

**iTeos Therapeutics**

**Corporate**
Spin off of Ludwig Cancer Research and de Duve Institute founded in 2011
$407M capital + €33M non dilutive funding
Listed on Nasdaq: ITOS
Headquarters in Cambridge, MA + R&D in Gosselies, Belgium
M Detheux, CEO; J Lager, CMO; M Call, COO; M Gall, CFO, Y McGrath, VP R&D

**Technology**
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients.

**Business**
Develop a sustainable pipeline with intraportfolio synergies and identify strategic partnership to accelerate and expand clinical development of our targets
A2A small molecule antagonist moving in phase 1b/2a in 3Q2020 in several indications & combinations
TIGIT antibody in phase 1

**Milestones**
A2A lead program showed clinical benefit in monotherapy in 2020
TIGIT phase 1 in 2Q2021
Targeting a clinical proof of concept for clinical programs in 2022-2023

**Contact Person:** Michel Detheux, michel.detheux@iteostherapeutics.com

**Visit our Website:** www.iteostherapeutics.com
iSTAR Medical

Corporate

**Founded** in 2010 with exclusive IP rights to STAR® material for Ophthalmology, developed at University of Washington, USA
HQ in Wavre, Belgium.

**FTE:** 25+

**Financing:** Series A,B,C in 2013, 2016, 2019. Total raised 55M€

**CEO:** Michel Vanbrabant.

Technology

**Implants to treat Glaucoma** with innovative, flexible, anti-fibrotic STAR® material, made of biocompatible, medical-grade silicone.

**MINject™ micro-invasive glaucoma surgery (MIGS) device** designed to reduce pressure in front of eye caused by fluid build-up, in order to prevent damage to optic nerve. It does this by redirecting excess fluid to a natural drainage pathway (uveoscleral outflow).

Business

**Objective** to be a best-in-class MIGS device for treatment of Glaucoma.

**Clinical Results**

- STAR-I Trial Results @ 2Y for MINject™ show sustained reduction of pressure by 40%, with 48% patients free of pressure-lowering medication.
- European STAR-II Trial @ 12M shows consistent results with STAR-I at same time point.
- No serious adverse events related to device or procedure; no patient required additional Glaucoma surgery

**CE Mark** filed in 2020

In Our Portfolio

Milestones

2021:
- CE-Mark approval
- EU Commercial Launch
- US IDE approval by FDA

> 2021
- Commercial Launch in non-EU territories as from 2023
- US Commercial Launch expected in 2025/2026.

Contact: Michel Vanbrabant (CEO) - info@istarmed.com - www.istarmed.com
In Our Portfolio

Imcyse

Corporate
Spin-off from the KU Leuven
Relocated to Liège in 2012
Completed Series B financing (EUR 28m) in 2019
Raised EUR 60m in equity, incl. loans and grants

Technology
Imotope™ technology; modified peptides eliciting cytolytic T cells
Addressing autoimmune diseases
Pre-clinical POC in several indications achieved
Clinical POC in type 1 diabetes

Business
Develop a sustainable and diverse pipeline with strategic collaborations to accelerate the clinical development of our targets
Phase 2 clinical program in type 1 diabetes started
R&D collaboration with Pfizer in rheumatoid arthritis

Milestones
Phase 2 clinical study in type 1 diabetes ongoing
Additional phase ½ studies including clinical proof of concept in other indications (Multiple Sclerosis, NMO, Rheumatoid Arthritis, Coeliac Disease) to be started in 2022-2023

Contact Person: Denis Bedoret, CEO - info@imcyse.com
Visit our Website: www.imcyse.com
Exothera

Corporate
Origin: Jumet
Fund raising since inception: cf. UNVC
Financial ratios: cf. UNVC
Management team: Hugues Bultot, Thibaut Jonckheere, Christian Borgniet

Technology
Area of interest: Cell & Gene Therapy
Services description: CDMO delivering customized process development and GMP manufacturing services for gene therapy and viral vector-based vaccines
Milestones/POC reached: company creation with 50 FTE, first successful client projects delivered

Business
Current R&D programs: N/A at the moment
Current market targets: Cell & gene therapy innovators, mainly the US and EU-based biotechs

Milestones
Next R&D /commercial steps to reach:
Launch of the GMP clinical and commercial manufacturing

Corporate objectives:
- Inauguration of 2 facilities on the Univercells Campus in Jumet.
- Hiring of 80 collaborators in 2021

In Our Portfolio

j.lecocq@exothera.world
www.exothera.world
In Our Portfolio

Diagenode

Corporate
Founded in Liège in 2004
Shareholder's equity: 7.2M€
Headcounts 2019: 120

Technology
Focus: Epigenetic for Life science and IVD diagnostic
Field of interest: Histone modifications, DNA methylation, and small non coding RNA analysis
Technologies: Next generation sequencing, Immunoprecipitation, QPCR, DNA shearing

Business
IVD Kits, Instruments, Kits & reagents, services
ISO 13485
CE Marked and FDA IVD kits
40% sales in the US
10% sales in China
3 subsidiaries:
- Diagenode Inc Denville New Jersey USA
- Diagenode KK Tokyo Japan
- Diagenode S.A. Santiago Chile

Milestones
2005: Diagenode Inc Denville New Jersey
2006: Launch of our first epigenetic kit
2011: First IVD assay development contract
2016: 5.5 million capital increase
2017: Diagenode KK Tokyo
2018: First FDA IVD kit approved

Contact: Didier Allaer, CEO
Visit our Website: www.diagenode.com
In Our Portfolio

ChromaCure

Corporate
Founded in 2018
Spin-off ULB (Prof. Cédric Blanpain)
17 millions EUR raised since incorporation

Technology
Area of interest: Targeted therapies
Products description: First-in-class small molecule

Business
Current R&D programs:
Lead program expected to reach clinical development in 2023

Milestones
2019: First milestone achieved

Contact Person: Jalal VAKILI (CEO), Jalal.Vakili@chromacure.com
Visit our Website www.chromacure.com
In Our Portfolio

Celyad Oncology

Corporate
Founded in 2007
€235 millions raised to date
Listed on Nasdaq & Euronext
100+ employees
Filippo Petti, CEO

Technology
Onco-immunotherapy focus
Use of C-type Lectins to generate CAR-T cells
Current clinical focus on the natural killer receptor NKG2D that recognizes eight different ligands expressed in 80% of cancers

Business
Lead product: autologous therapy CYAD-01 leveraging the NKG2D receptor in the treatment of r/r AML and MDS (phase 1)
CYAD-101, non-gene edited, allogeneic (healthy donor derived) CAR-T therapy for the treatment of solid cancers (phase 1)
Next generation autologous therapy CYAD-02 phase 1 started in January 2020

Milestones
Accelerate the clinical development of CYAD-01 for the treatment of r/r AML and focus on path to commercialization
Next generation non gene edited shRNA-based allogeneic CARs (CYAD-200 series) to enter the clinic

Contact: Alexandrine Hazard, Communications & Investor Relations – investors@celyad.com
Visit our Website: www.celyad.com
Bone Therapeutics SA

Corporate

Origin:
Founded in 2006 as spin-off of ULB

Fund raising since inception:
111M €

Listing:
Euronext Brussels & Paris (BOTHE)

Management team:
Miguel Forte, MD, PhD (CEO),
Jean-Luc Vandebroek (CFO),
Stefanos Theoharis, PhD (CBO)
Sven Kili, MD (interim CMO),
Anne-Sophie, PhD (Head of Operations)

Technology

Area of interest:
Biotechnology, Cell Therapy, Orthopaedics, Bone diseases

Product description:
ALLOB, an allogeneic bone-cell therapy platform for orthopaedic conditions;
JTA-004, an improved viscosupplement with plasma protein solution for knee osteoarthritis;
BT-20, an allogeneic Mesenchymal Stromal Cell (MSC) based therapy targeting inflammatory conditions.

Business

Current market targets:
Orthopaedic conditions with high unmet medical needs and limited innovation:
- Difficult fractures: 700K patients p.a.
- Knee osteoarthritis: 27M patients
  (EUS, USA and Japan)

Milestones

Current R&D programs and next R&D steps to reach:
- Positive safety and efficacy in 2 Phase IIa studies with ALLOB for the treatment of delayed-union fractures and in spinal fusion procedures.
- Positive Phase IIb controlled efficacy results with JTA-004 in knee osteoarthritis, showing a superior improvement in pain relief compared to a leading viscosupplement.
  → Patient recruitment of pivotal Phase III study in knee osteoarthritis treating >700 patients completed in December 2020. Topline results expected in Q3-2021.

Contact Persons: Miguel Forte (CEO); Jean-Luc Vandebroek (CFO); Stefanos Theoharis (CBO) | investorrelations@bonetherapeutics.com - +32 71 12 10 00
Visit our Website: www.bonetherapeutics.com

In Our Portfolio
A-Mansia Biotech

Technology
Field of expertise: Microbiota
Food Supplements to decrease cardiometabolic risks associated with obesity based on an innovative bacteria isolated from Humans: Akkermansia muciniphila

Business
Nutrition Focus:
- A platform of food supplement products in metabolic field
- Current market targets: Branded sales under HCPs’ recommendation (Europe and Rest of the world)

In Our Portfolio

Corporate
Co-spin off UCLouvain-Wageningen Universiteit
€18M in 2018
€ 5M non dilutive in 2018-19
Cees de Jong - Chairman
JC. Malrieu - CEO
P. Cani – W. de Vos - Founders

Milestones
Next important steps:
> Novel Food validation by European Food Safety Agency
> Nutritional Clinical studies in Metabolic health

Corporate objectives:
> Enter European market with food supplements targeting unmet needs in 2022

Jean-Christophe.Malrieu@a-mansia.com
Visit our Website www.a-mansia.com
Choose Life!